DEDHAM, Mass.--(BUSINESS WIRE)--Qlaris Bio, Inc., a clinical‐stage biotechnology company dedicated to developing first‐in‐class therapies for glaucoma, today announced that new data from studies of ...
QLS-111’s novel intraocular pressure-lowering mechanism targeting EVP to be highlighted in an oral presentation and two poster presentations DEDHAM, Mass., June 23, 2025--(BUSINESS WIRE)--Qlaris Bio, ...
Qlaris Bio, Inc., a clinical‐stage biotechnology company dedicated to developing first‐in‐class therapies for glaucoma, today announced that new data from studies of its lead investigational compound ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback